For a study, researchers sought to examine the association between pre-admission statin use and inflammation, myocardial injury indicators, and clinical outcomes in COVID-19-admitted patients with established atherosclerosis. Adults diagnosed with coronary artery disease, peripheral arterial disease, or atherosclerotic cerebrovascular disease who were hospitalized with COVID-19 between March 1, 2020, and December 31, 2020, were included in the study. The usage of statins was found to be associated with the primary composite clinical outcome, which might be mortality, hospitalization in an intensive care unit, or thrombotic problems, depending on which multivariable logistic regression model was used. About 1,360 of the 3,584 adult patients hospitalized with COVID-19 satisfied the study inclusion criteria (mean age 73.8 years, 45% women, 68% White). Before admission, troponin and C-reactive protein levels were lower in individuals taking statins. In an unadjusted model, statin use before admission was associated with a significant reduction in the primary composite outcome (42.2% vs. 53.7%, odds ratio 0.63 [95% CI 0.50 to 0.80], P<0.001). This association remained significant after adding age, gender, ethnicity, other patient clinical characteristics, and cardiovascular medications to the model. Still, it became null when troponin and C-reactive protein were also included (odds ratio 0.83 [95% CI 0.63 to 1.01] P=0.18). In conclusion, pre-admission statin medication was connected with an improved in-hospital outcome among patients with preexisting cardiovascular disease who were admitted with COVID-19. However, this relationship was eliminated when inflammation and myocardial injury were considered.
- Business of Medicine
- Doctor’s Voice